Silicon Investor (SI) -- The First Internet Community

5/4/2012 3:17:23 PM

From: idos

Not only the malignancy risk also sounds like the FDA is not impressed by efficacy:
"However, the magnitude of the absolute treatment effect is small, both in terms
of the primary endpoint, secondary, and selected exploratory endpoints."